Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Any bleeding that does not meet criteria for major bleeding ‐ Gastrointestinal bleeding (no definition) · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes any bleeding that does not meet criteria for major bleeding ‐… compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with dual antiplatelet agent (very low certainty).
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether dual antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) probably leads to higher strokea compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Mean quality of life ‐ health utility · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
1 finding from 1 review
Mean quality of life ‐ health state · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in clinically relevant non‐major bleeding compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Thromboembolic events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in any thromboembolic event compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in major bleeding compared with standard‐dose VKA (low certainty).
1 finding from 1 review